StockTipsArenaBeta

BUY Divi's Laboratories Limited — Nuvama Wealth

BUYDivi's Laboratories Limited
Divi's Laboratories share price target & all analyst calls

byNuvama WealthHorizon: NA (inferred 1 year)3 Aug 2026via ET Now (Live)

Entry₹8,380Inferred
Target₹9,600
Total upside +14.56% (call closed)
Stop lossNot given
Exit₹9,6009 Sept 2026, 12:09 pm
Target hit+14.56%0.00%upside left
Follow Nuvama Wealth for new calls(69% target hit, 144 closed calls)Get alertsWatch DIVISLAB for new buy/sell callsGet alertsSee 7 active Long-term calls on DIVISLABSee 209 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Sept 2026
15 supporting11 neutral2 opposing
Supports the BUY call (15)

Divi's Laboratories posts 65% PAT surge in Q1FY27 on strong revenue growth

NewsGoogle News·6 Sept · 2d ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · 2w ago

PNB Housing, Divi's Labs Touch 52-Week Highs on Aug 26

NewsGoogle News·26 Aug · 2w ago

(opens in new tab)

Divi’s, TVS Motors, Dixon See Bullish Signals: Analyst

NewsGoogle News·26 Aug · 2w ago

(opens in new tab)

Divis Laboratories fixes July 24 record date for ₹30 dividend

NewsGoogle News·25 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (11)

Nifty 24,500 पर फिसला, Divi's, MCX और Eternal पर रखें नज़र!

NewsGoogle News·12 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

Indian Pharma Stocks Face Volatility After US Tariff Proposal

NewsGoogle News·14 Aug · 4w ago

(opens in new tab)

4 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·3 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Divi's Laboratories

All analyst calls on Divi's Laboratories

More from Nuvama Wealth

Every call and its outcome